Literature DB >> 21128082

Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis.

J Dorst1, P Kühnlein, C Hendrich, J Kassubek, A D Sperfeld, A C Ludolph.   

Abstract

Weight loss is a common phenomenon and an independent prognostic factor in amyotrophic lateral sclerosis (ALS). Several potential causal mechanisms, including intrinsic hypermetabolism and deficient food intake, have been discussed. We investigated the influence of fasting serum glucose, cholesterol, and triglyceride levels at time of diagnosis on survival in ALS. Serum cholesterol (LDL, HDL, and LDL/HDL ratio), triglycerides, and glucose were investigated in 488 patients (age of onset = 57.6 ± 12.6 years) in relation to survival and revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALS-FRS) data. High serum levels of both fasting cholesterol and triglycerides had a significantly positive effect on survival (p < 0.05). We found a median prolonged life expectancy by 14 months for patients with serum triglyceride levels above the median of 1.47 mmol/l. The results suggest that the lipid metabolism and the nutritional status of ALS patients are important prognostic factors. These parameters should be thoroughly monitored during the clinical management of these patients. In case of progressive loss of body weight, a diet rich in lipids and calories should be considered. However, the final decision whether a lipid-rich diet should be recommended to ALS patients can only be based on a double-blind placebo-controlled interventional trial. Our results further imply that lipid-lowering drugs, e.g., statins, should be applied carefully in ALS patients although individual risk considerations must be made.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21128082     DOI: 10.1007/s00415-010-5805-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS.

Authors:  Ali Jawaid; Santosh B Murthy; Andrew M Wilson; Salah U Qureshi; Moath J Amro; Michael Wheaton; Ericka Simpson; Yadollah Harati; Adriana M Strutt; Michele K York; Paul E Schulz
Journal:  Amyotroph Lateral Scler       Date:  2010-05-26

3.  Carbohydrate metabolism in motor neurone disease.

Authors:  D Saffer; J Morley; P L Bill
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-06       Impact factor: 10.154

4.  Nutritional status is a prognostic factor for survival in ALS patients.

Authors:  J C Desport; P M Preux; T C Truong; J M Vallat; D Sautereau; P Couratier
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Impaired glucose tolerance in patients with amyotrophic lateral sclerosis.

Authors:  Pierre-Francois Pradat; Gaelle Bruneteau; Paul H Gordon; Luc Dupuis; Dominique Bonnefont-Rousselot; Dominique Simon; Francois Salachas; Philippe Corcia; Vincent Frochot; Jean-Marc Lacorte; Claude Jardel; Christiane Coussieu; Nadine Le Forestier; Lucette Lacomblez; Jean-Philippe Loeffler; Vincent Meininger
Journal:  Amyotroph Lateral Scler       Date:  2010

6.  Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis.

Authors:  J C Desport; P M Preux; L Magy; Y Boirie; J M Vallat; B Beaufrère; P Couratier
Journal:  Am J Clin Nutr       Date:  2001-09       Impact factor: 7.045

7.  Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.

Authors:  Luc Dupuis; Hugues Oudart; Frédérique René; Jose-Luis Gonzalez de Aguilar; Jean-Philippe Loeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

8.  Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.

Authors:  L Dupuis; P Corcia; A Fergani; J-L Gonzalez De Aguilar; D Bonnefont-Rousselot; R Bittar; D Seilhean; J-J Hauw; L Lacomblez; J-P Loeffler; V Meininger
Journal:  Neurology       Date:  2008-01-16       Impact factor: 9.910

9.  Abnormalities of lipoprotein and carbohydrate metabolism in degenerative diseases of the nervous system--motor neuron disease and spinocerebellar degeneration.

Authors:  A Murai; T Miyahara; T Tanaka; T Kaneko; Y Sako; M Kameyama
Journal:  Tohoku J Exp Med       Date:  1983-04       Impact factor: 1.848

10.  Lower serum lipid levels are related to respiratory impairment in patients with ALS.

Authors:  A Chiò; A Calvo; A Ilardi; E Cavallo; C Moglia; R Mutani; A Palmo; R Galletti; K Marinou; L Papetti; G Mora
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

View more
  85 in total

Review 1.  [Amyotrophic lateral sclerosis. Multisystem degeneration].

Authors:  A Hübers; A C Ludolph; A Rosenbohm; E H Pinkhardt; J H Weishaupt; J Dorst
Journal:  Nervenarzt       Date:  2016-02       Impact factor: 1.214

2.  Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans.

Authors:  Daniela Mariosa; John D Beard; David M Umbach; Rino Bellocco; Jean Keller; Tracy L Peters; Kelli D Allen; Weimin Ye; Dale P Sandler; Silke Schmidt; Fang Fang; Freya Kamel
Journal:  Am J Epidemiol       Date:  2017-03-01       Impact factor: 4.897

3.  Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study.

Authors:  Johannes Dorst; Luc Dupuis; Susanne Petri; Katja Kollewe; Susanne Abdulla; Joachim Wolf; Markus Weber; David Czell; Christian Burkhardt; Frank Hanisch; Stefan Vielhaber; Thomas Meyer; Gabriele Frisch; Dagmar Kettemann; Torsten Grehl; Bertold Schrank; Albert C Ludolph
Journal:  J Neurol       Date:  2015-01-25       Impact factor: 4.849

Review 4.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

Review 5.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

6.  Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Theodore Hyman; Amy Shui; Peggy Allred; Matthew Harms; Jingxia Liu; Nicholas Maragakis; David Schoenfeld; Hong Yu; Nazem Atassi; Merit Cudkowicz; Timothy M Miller
Journal:  Muscle Nerve       Date:  2015-06-01       Impact factor: 3.217

7.  Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis.

Authors:  Jessica Mandrioli; Edoardo Rosi; Nicola Fini; Antonio Fasano; Silvia Raggi; Anna Laura Fantuzzi; Giorgio Bedogni
Journal:  Neurol Sci       Date:  2017-10-04       Impact factor: 3.307

8.  Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Jing Deng; Matthew Jaffa; Merit E Cudkowicz; Anne-Marie Wills
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

9.  Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice.

Authors:  Hui Sun; Sarah Knippenberg; Nadine Thau; Daniela Ragancokova; Sonja Körner; Dongya Huang; Reinhard Dengler; Klaus Döhler; Susanne Petri
Journal:  Cell Mol Neurobiol       Date:  2012-12-28       Impact factor: 5.046

10.  Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Authors:  Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.